Sanofi (SNY) Gross Margin (2009 - 2026)

Sanofi has disclosed Gross Margin across 18 years of filings, most recently posting 80.05% for Q2 2026.

• In Q2 2026, Gross Margin rose 257.0% year-over-year to 80.05%; the TTM figure through Jun 2026 stood at 77.65% (down 64.0% YoY), while the FY2025 annual figure was 77.17%, up 151.0% from the prior year.
• Gross Margin came in at 80.05% for Q2 2026 at Sanofi, up from 77.13% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 87.1% in Q4 2023 to a low of 63.67% in Q4 2022.
• Average Gross Margin over 5 years is 76.78%, with a median of 76.38% recorded in 2023.
• Year-over-year, Gross Margin slumped 829 bps in 2022 and jumped 2343 bps in 2023.
• Over 5 years, Gross Margin stood at 63.67% in 2022, then jumped by 37 bps to 87.1% in 2023, then retreated by 4 bps to 83.31% in 2024, then dropped by 2 bps to 81.66% in 2025, then declined by 2 bps to 80.05% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 80.05% in Q2 2026, 77.13% in Q1 2026, and 81.66% in Q4 2025.